Intellia Therapeutics/$NTLA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Intellia Therapeutics
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Ticker
$NTLA
Sector
Primary listing
Employees
403
Headquarters
Website
NTLA Metrics
BasicAdvanced
$1.5B
-
-$4.68
2.32
-
Price and volume
Market cap
$1.5B
Beta
2.32
52-week high
$28.25
52-week low
$5.90
Average daily volume
9M
Financial strength
Current ratio
5.193
Quick ratio
4.932
Long term debt to equity
10.57
Total debt to equity
14.343
Profitability
EBITDA (TTM)
-501.874
Gross margin (TTM)
-679.72%
Net profit margin (TTM)
-908.48%
Operating margin (TTM)
-968.69%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-30.62%
Return on equity (TTM)
-56.95%
Valuation
Price to revenue (TTM)
26.325
Price to book
2
Price to tangible book (TTM)
2
Price to free cash flow (TTM)
-3.299
Free cash flow yield (TTM)
-30.32%
Free cash flow per share (TTM)
-4.114
Growth
Revenue change (TTM)
14.99%
Earnings per share change (TTM)
-14.49%
3-year revenue growth (CAGR)
5.25%
3-year earnings per share growth (CAGR)
-4.42%
What the Analysts think about NTLA
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
Bulls say / Bears say
NTLA-2002 Phase 1/2 data demonstrated dramatic, dose-dependent and durable reductions in kallikrein levels suggesting a potential functional cure for hereditary angioedema, and interim Phase 1 results for nex-z showed rapid, deep and durable serum TTR reductions in ATTR patients (Nasdaq).
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to nex-z for ATTR-CM, offering early interactions with the agency and potential priority review of its BLA to accelerate development (GlobeNewswire).
Jones Trading analyst Debanjana Chatterjee believes the FDA clinical hold on Intellia’s Phase 3 trials has limited long-term impact and expects trial activities to resume within a few months (Reuters).
The U.S. FDA placed a clinical hold on Intellia’s two late-stage gene-editing trials after a patient experienced Grade 4 liver enzyme elevations and high bilirubin levels, pausing dosing and screening (Reuters).
Intellia’s stock plummeted 40% after pausing its two Phase 3 clinical trials for nex-z due to a serious safety issue, underscoring significant valuation risk tied to its lead asset (Barron’s).
A January 9, 2025 strategic review led Intellia to discontinue NTLA-3001 and other early-stage programs and reduce its workforce by approximately 27%, narrowing its pipeline and increasing execution risk (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
NTLA Financial Performance
Revenues and expenses
NTLA Earnings Performance
Company profitability
NTLA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intellia Therapeutics stock?
Intellia Therapeutics (NTLA) has a market cap of $1.5B as of November 06, 2025.
What is the P/E ratio for Intellia Therapeutics stock?
The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of November 06, 2025.
Does Intellia Therapeutics stock pay dividends?
No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Intellia Therapeutics dividend payment date?
Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Intellia Therapeutics?
Intellia Therapeutics (NTLA) has a beta rating of 2.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.